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Abstract 
Background: Arguments have continued about Low Carbohydrate Diet (LCD) and Calorie Restriction (CR). Authors have 
reported clinical research of LCD and Morbus (M) value. 
Subjects and Methods: Subjects enrolled are 84 patients with Type 2 diabetes mellitus (T2DM), 60.9 ± 10.9 years. The protocol 
were as follows: 1) CR diet on day 1, 2 with 60% carbohydrates, and LCD on day 3-14 with 12% carbohydrates, 2) Daily profile 
of blood glucose 7 times a day on day 2 (CR) and day 4 (LCD), 3) urinary C-Peptide radioimmunoassay (u-CPR) excretion, 4) M 
value calculation, 5) investigation of these data with correlation.  
Results: Subjects were classified into 4 groups according to M value, which were .4–21, 23–66, 29–192, 200–728, respectively. 
HbA1c value was 6.2, 8.0, 7.8, 9.2 %, respectively. Blood glucose in median from day 2 to day 4 were 123 to 107 mg/dL, 164 to 
130 mg/dL, 193 to 156 mg/dL, 277 to 201 mg/dL, respectively. M value in median from day 2 to 4 was 6.3 to 9, 41 to 7, 108 to 
16, 367 to 88, respectively. u-CPR was 88 to 58, 53 to 35, 65 to 52, 74 to 64, respectively. There were significant correlations 
among among glucose, M value and u-CPR. 
Discussion and Conclusion: Average glucose, M value and u-CPR decreased remarkably on day 4. As average glucose and M 
value were higher, decrease degree were larger. These results suggested that carbohydrate in meal would influence glucose 
variability in T2DM. Our data would become basic data for pathophysiological analysis of glucose variability research in the 
future. 
Keywords: Urinary C-peptide (u-CPR); Low Carbohydrate Diet (LCD); Morbus value (M value); type 2 diabetes mellitus (T2DM); Average Glucose 
(AG) 
Abbreviation: CPR: C-Peptide immunoreactivity, LCD: Low-Carbohydrate Diet, CR: Calorie-Restricted, T2DM: Type 2 Diabetes Mellitus, T1DM: 
Type 1 Diabetes Mellitus, M value: Morbus value, MAGE: Mean Amplitude of Glycemic Excursions, HOMA-R: Homeostasis model assessment-Insulin 
Resistance, HOMA-β: Homeostasis model assessment of β-cell function. 
Introduction 
For years, there has been discussions concerning Low 
Carbohydrate Diet (LCD) and Calorie Restriction (CR). 
Recent reports have showed efficacy of LCD such as 
randomized controlled trials, systematic review and meta-
analyses [1-3]. 
Historically, Atkins and Bernstein originally have started 
LCD in western countries [4,5]. Consecutively, clinical 
predominance of LCD have been shown by investigators 
[6-9]. Furthermore, LCD has been applied widely to several 
diseases and impaired states, such as metabolic syndrome 
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(Met-S), obesity, nonalcoholic fatty liver disease 
(NAFLD), cardiovascular disease, and so on [10-12] 
On contrast, in Japan, the author have firstly introduced and 
reported LCD for T2DM in Japan and developed LCD in 
lots of opportunities [13,14]. Subsequently, we reported 
clinical studies concerning LCD with pathophysiological 
aspects [15-18].  
In current study, we investigated urinary C-Peptide 
immunoreactivity (u-CPR) excretion in patients with Type 
2 Diabetes mellitus (T2DM). Simultaneously, we measured 
the average glucose and Morbus (M) value, and studied the 
detail correlation among these biomarkers.  
 
Subjects and Methods 
In current study, the subjects included 84 patients with 
T2DM, which were 33 males and 51 females. They are 28-
84 years old (yo) with 60.9 ± 10.9 (mean +/- SD) yo. in 
average, 63 yo in the median value.  
Subjects were enrolled from the in-patients of the 
educational admission for further evaluation and treatment 
of T2DM. The protocol of diet therapy were as follows:  
 
1) CR diet was provided on day 1 and 2, which 
had 60% carbohydrates, 25% lipids and 15% protein with 
1400 kcal/day.  
2) LCD was provided from 3 to 14 days, which 
had 12% carbohydrates, 64% lipids and 24% protein with 
1400 kcal/day.  
3) This LCD has been called “super-LCD 
formula” in our clinical research for LCD, which is one of 
the Very low-carbohydrate ketogenic diet (VLCKD) by the 
definitions of LCD [13-16].  
 
Examinations included several kinds of glucose 
metabolism. The are 1) several basal biomarkers on 
admission, 2) daily profile of blood glucose 7 times a day 
on day 2 (CR) and day 4 (LCD), 3) u-CPR were measured 
on day 2 and day 4, 4) M value was calculated from blood 
glucose level. 
 
Morbus (M) value 
Data obtained from daily profile of blood glucose were 
calculated into Morbus (M) value. M value is the index 
which represents both blood sugar level and mean 
amplitude of glycemic excursions (MAGE) [19-22]. 
Regarding glucose variability, daily profiles of blood 
glucose has been measured 7 times a day, which data were 
calculated into average glucose and M value. M value has 
been proposed for researching average glucose and MAGE. 
This index has been calculated as a logarithmic 
transformation of the deviation of glycemia from an 
arbitrary assigned “ideal” glucose value. Clinically, ideal 
glucose level would be around 120 mg/dL, then M value 
uses 120 mg/dL for the standard level. Consequently, M 
value expresses both the average glucose value and the 
effect of glucose swings [19-22]. 
M value is calculated by the following formula: M = MBS 
+ MW, where MW = (maximum blood glucose−minimum 
glucose)/20; MBS = the mean of MBSBS; MBSBS = 
individual M-value for each blood glucose value calculated 






Concerning the interpretation of M value, the standard range 
would be <180, borderline 180-320 and abnormal >320. 
Adequate sampling times a day have been argued for detail and 
precise evaluation of glucose variability and MAGE. Similar 
results were found on 7 times or 20 times of sampling per day 
[19,22,23]. It also revealed similar results compared with the 
continuous glucose monitoring (CGM) [22,24]. 
 
Statistical analyses 
In this study, obtained data was represented as the mean +/- 
standard deviation (SD) and also represented median, quartile 
of 25% and 75% in biomarkers. For statistical analyses, 
correlation coefficients were calculated using Pearson or 
Spearman test of the Microsoft Excel analytical tool, which is 
Four steps Excel Statistics 4th edition [25]. A significance 




This study was conducted in compliance with the ethical 
principles of the Declaration of Helsinki. It was also along with 
Japan’s Act on the Protection of Personal Information along 
with the Ministerial Ordinance on Good Clinical Practice 
(GCP) for Drug (Ordinance of Ministry of Health and Welfare 
No. 28 of March 27, 1997). Ethical committee meeting was 
held by physician, researchers, medical staff and legal expert. 
Informed consent was obtained from the subjects. The study 
was registered with UMIN #R000031211. 
 
Results 
Subjects were classified into 4 groups according to M value. 
Data of M value in 4 groups were, 4–21, 23–66, 29–192, 200–
728, respectively (Table 1). Each group has 21 subjects, and 
other results of biomarkers were shown in Table 1. 
 
Data are expressed mean standard deviation, and also meadian [25%-75%]. 
Table 1: Basal data of the subject classified into 4 groups. 
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Fasting blood glucose and HbA1c value increased from 
group 1 to group 4 in order (Figure 1). Each median value 
was 114, 137, 163, 216 mg/dL, and 6.2, 8.0, 7.8, 9.2%, 
respectively. The average glucose on day 4 was decreased 
from that on day 2 in 4 groups (Figure 2). Average glucose 
in median from day 2 to day 4 in each group was 123 to 
107 mg/dL, 164 to 130 mg/dL, 193 to 156 mg/dL, 277 to 
201 mg/dL, respectively.  
When calculated on daily profile of blood glucose into M 
value, it decreased from day 2 to day 4 in group 2,3 and 4 
(Figure 3). M value in median from day 2 to day 4 in each 
group was 6.3 to 9, 41 to 7, 108 to 16, 367 to 88, 
respectively.  
 U-CPR on day 2 and day 4 are shown in Figure 4. In each 
group, decreased value from day to day 4 was 88 to 58, 53 
to 35, 65 to 52, 74 to 64, respectively. 
There is significant correlation between blood glucose in 
average on day 2 and day 4 (p<0.01) (Figure 5a). There is 
significant correlation between blood glucose in average 
and HbA1c (p<0.01) in which the regression curve showed 
y = 0.02 x + 4.2 (Figure 5b).  
 
1a: Fasting blood glucose increases from group 1 to 4. 
 
2a: HbA1c value increases from group 1 to 4. 
Figure 1: Blood glucose and HbA1c in 4 groups. 
 
 
G-1 day2: Group 1 on day 2 (CR), G-4 day4: Group 4 on day 4 (LCD). 
Figure 2: The changes of average blood glucose on day 2 and day 
4 in 4 groups.        
 
Figure 3: The changes of M value on day 2 and day 4 in 4 groups. 
 
 
U-CPR: urinary C-peptide immunoreactivity,  
Figure 4: The changes of U-CPR excretion on day 2 and day 4 in 
4 groups. 
 
5a: Correlation between blood glucose in average on day 2 and day 
4. 
 
5b: Correlation between blood glucose in average and HbA1c. 
Figure 5: Correlation between blood glucose and HbA1c. 
Significant correlation was observed between u-CPR on 
day 2 (CR) and day 4 (LCD) (p<0.01), in which the 
regression curve showed y=0.75x + 4.5 (Figure 6a). There 
is no significant correlation of ratio for day 4 to day 2 
between average glucose and u-CPR (Figure 6b). 
 
There is significant correlation between M value on day 2 
and day4 (p<0.01) (Figure 7a). There is no significant 
correlation of ratio of day 2 and 4 between M value and u-
CPR (Figure 7b). 
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6a: Correlation between u-CPR on day 2 (CR) and day 4 (LCD). 
 
6b: Correlation of ratio for day 4 to day 2 between average glucose and u-
CPR. 
Figure 6: Correlation of u-CPR and blood glucose. 
 
7a: Correlation between Morbus (M) value on day 2 and day4. 
 
7b: Correlation of ratio of day 2 and 4 between M value 
and u-CPR. 




Recently, fundamental and clinical research of LCD have 
been developed and prevalent [26,27], and we have 
continued research for LCD with proposal for medical 
practice [28-30].  
In this study, we examined changes in average glucose, M 
value, urinary CPR in 2 days after diet changed from CR to 
LCD. We also investigated the correlation among these 
biomarkers, and clarified efficacy of LCD for the 
improvement of the profile of blood glucose in short 
period. 
M value has been useful marker that would evaluated 
elevated blood glucose and increased MAGE. In this 
diabetic research field, we have continued to study the 
detail of glucose variability using M value [18,30,31]. 
As for current study, we divided into 4 groups according to 
M value. Group 1 was mild, and group 4 was severe in 
degree of diabetes. In Groups 2, 3 and 4, mean glucose and 
M values clearly decreased from day 2 to 4. On contrast, 
group 1 includes mild diabetes or pre-diabetic subjects. In 
other words, it seems that blood glucose and HbA1c are 
close to normal people, and the insulin secretion ability is 
preserved proportionally. 
 In group 1, blood sugar in median decreased from 123 to 
107 mg/dL, and u-CPR decreased remarkably from 88 to 
55 mg/day. For meal protocols, CR for day 1, 2. and LCD 
for day 3,4 were provided. In comparison of day 2 and day 
4, the carbohydrate ratio is 60% vs. 12%, the carbohydrate 
amount per day is 210 g vs. 42 g. This difference in 
carbohydrate intake possibly leads to lowering of blood 
glucose and lowering of CPR in urine, with mutual 
correlation. 
  
Average glucose decreased in group 1 from day 2 to day 4, 
but the M value did not decrease. The reason would be that 
the M value is calculated with the absolute value of blood 
glucose away from 120 mg / dL, which is ideal blood 
glucose level. 
Actually, several cases in group 1 showed almost normal 
range of blood glucose at day 2. These cases developed 
decreased blood glucose around 80-100 mg/L at day 4. 
That is why M value in group 1 did not decrease from day 
2 to day 4 [32,33]. 
 
In the protocol of this study, diet therapy was changed from 
CR to LCD for T2DM. Among them, the main 
investigation were u-CPR measurements in 2 days apart, 
and it was possible to analyze the relationship with mean 
blood sugar and M value simultaneously. As a result, the 
reduction in carbohydrate intake decreased blood glucose 
level and glucose fluctuation, especially leading to a drastic 
decrease in M value.  
In addition, insulin secretion was suppressed due to a 
decrease in blood glucose spike, leading to decreased u-
CPR excretion which is an indicator of insulin secretion. 
From the above, it can be said that the series of 
pathophysiological pathway in diabetes has been improved 
in the short term. These results suggest that LCD would 
have remarkable efficacy for nutritional treatment of 
diabetes. 
 
Significant correlation between blood glucose in average 
and HbA1c (p<0.01) was observed. Its regression curve 
would indicate that HbA1c (%) = 0.02 x AG (mg/dL) + 4.2. 
When x axis and y axis changes each other, the equation 
becomes “AG = 25.3 x HbA1c – 12.2”.  
 Well-known equation has been reported by Nathan et al. 
which was “AG = 28.7 x HbA1c – 46.7” analyzed from 
2700 samples [34]. As a comparison, substitute HbA 1 c = 
7, 8, 9% into our formula and Nathan's formula. Then, the 
result is 165.1 vs 154.2 mg / dL, 190.2 vs 182.9 mg / dL, 
215.5 vs 211.6 mg / dL, and both estimated values are near 
and compatible. 
We measured average blood glucose 7 times a day. It is 
said that the difference from the measurement of 20 times 
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in the past is small and that the reliability is actually high. 
The subjects in this research were 84 cases of type 2 
diabetes, including cases where HbA1c was low. Several 
cases in group 1 may showed lower HbA1c and blood 
glucose may be a higher than that of normal subjects which 
has the same HbA1c level. 
On the other hand, study by Nathan et al. included type 1 
diabetes, type 2 diabetes and normal individuals. Therefore, 
in regions where HbA1c is low, blood sugar levels are 
expected to be lower because there are many samples of 
normal subjects. Actually, if we enter 6% as HbA1c level 
into both formulas of ours and Nathan, data would be 139.6 
mg/dL vs 125.5 mg/dL. 
U-CPR has been a simple and useful test in the diagnosis of 
diabetes [35]. It has been said that u-CPR and serum CPR 
has been said to be highly correlated [36]. Recently, 
measurement of u-CPR with creatinine would be 
recommended for more accurate result [37,38]. . 
C-peptide is clinically simple, noninvasive and useful 
examination for diabetes. Its application would be 
spreading in various situation, such as outpatient, in-
patients and postprandial measurements [39-41]. 
 
Conclusion 
In this study, we reported the changes in average glucose, 
M value and urine CPR value after meal change from CR 
to LCD. Associated with several correlation among them, 
and our results would become basic data for 
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